3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
13
Gynecologic
3
Breast
2
Head & Neck
1
Genitourinary
1
CNS
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Endometrial Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
pembrolizumab
28
Trastuzumab
16
Paclitaxel
14
Docetaxel
12
Cyclophosphamide
11
Capecitabine
11
Nivolumab
9
fludarabine
7
Carboplatin
7
Oxaliplatin
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
Specimen Handling
5
Leucovorin
5
Irinotecan
5
Injections
5
Gemcitabine
5
Fluorouracil
5
Bevacizumab
5
atezolizumab
4
aldesleukin
4
Taxes
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Drug Therapy
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
zanidatamab
3
veliparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
lenvatinib
×
Breast
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled